The IL-2/IL-2R System: from Basic Science to Therapeutic Applications to Enhance Immune Regulation

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2013 Nov 12

PMID 24214027

Citations 43

Authors

Allison L Bayer

Alberto Pugliese

Thomas R Malek

Affiliations

Soon will be listed here.

Abstract

IL-2 plays a critical role in the normal function of the immune system. A trophic factor for lymphocytes, IL-2 is required for mounting and sustaining adaptive T cell responses; however, IL-2 is also critical for immune regulation via its effects on regulatory T cells (Treg cells). Over the years, we have contributed to the understanding of the biology of IL-2 and its signaling through the IL-2 receptor and helped define the key role played by IL-2 in Treg development and function. Our data show that Treg cells have a heightened sensitivity to IL-2, which may create a therapeutic window to promote immune regulation by selective stimulation of Treg cells. We are now developing new efforts to translate this knowledge to the clinical arena, through our focused interest in Type 1 diabetes as a prototypic autoimmune disease. Specifically, we aim at developing IL-2-based therapeutic regimens and incorporate means to enhance antigen-specific Treg responses, for improved and more selective regulation of islet autoimmunity. In parallel, we are pursuing studies in preclinical models of autoimmunity and transplantation to define critical factors for successful adoptive Treg therapy and develop clinically applicable therapeutic protocols.

Citing Articles

Raffinose Ameliorates DSS-Induced Colitis in Mice by Modulating Gut Microbiota and Targeting the Inflammatory Signaling Pathway.

Zhang P, Xue Y, Cao Z, Guo Y, Pang X, Chen C Foods. 2024; 13(12).

PMID: 38928791 PMC: 11203344. DOI: 10.3390/foods13121849.

Clinical Efficacy of Extracellular Vesicle Therapy in Periodontitis: Reduced Inflammation and Enhanced Regeneration.

Puletic M, Velikic G, Maric D, Supic G, Maric D, Radovic N Int J Mol Sci. 2024; 25(11).

PMID: 38891939 PMC: 11171522. DOI: 10.3390/ijms25115753.

Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities.

Cassar E, Kartikasari A, Plebanski M Cancers (Basel). 2022; 14(22).

PMID: 36428581 PMC: 9688690. DOI: 10.3390/cancers14225488.

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.

Fanton C, Furie R, Chindalore V, Levin R, Diab I, Dixit N J Transl Autoimmun. 2022; 5:100152.

PMID: 35517914 PMC: 9062472. DOI: 10.1016/j.jtauto.2022.100152.

Contrast Enhanced Ultrasound Molecular Imaging of Spontaneous Chronic Inflammatory Bowel Disease in an Interleukin-2 Receptor α Transgenic Mouse Model Using Targeted Microbubbles.

Wang H, Vilches-Moure J, Bettinger T, Cherkaoui S, Lutz A, Paulmurugan R Nanomaterials (Basel). 2022; 12(2).

PMID: 35055297 PMC: 8779209. DOI: 10.3390/nano12020280.

References

Garg G, Tyler J, Yang J, Cutler A, Downes K, Pekalski M . Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. J Immunol. 2012; 188(9):4644-53. PMC: 3378653. DOI: 10.4049/jimmunol.1100272. View

Roep B, Peakman M . Diabetogenic T lymphocytes in human Type 1 diabetes. Curr Opin Immunol. 2011; 23(6):746-53. DOI: 10.1016/j.coi.2011.10.001. View

Koreth J, Matsuoka K, Kim H, McDonough S, Bindra B, Alyea 3rd E . Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011; 365(22):2055-66. PMC: 3727432. DOI: 10.1056/NEJMoa1108188. View

Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano R . Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010; 59(4):947-57. PMC: 2844842. DOI: 10.2337/db09-0498. View

Fletcher A, Lukacs-Kornek V, Reynoso E, Pinner S, Bellemare-Pelletier A, Curry M . Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J Exp Med. 2010; 207(4):689-97. PMC: 2856033. DOI: 10.1084/jem.20092642. View

Pierson W, Cauwe B, Policheni A, Schlenner S, Franckaert D, Berges J . Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3⁺ regulatory T cells. Nat Immunol. 2013; 14(9):959-65. PMC: 4128388. DOI: 10.1038/ni.2649. View

Ziegler A, Rewers M, Simell O, Simell T, Lempainen J, Steck A . Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013; 309(23):2473-9. PMC: 4878912. DOI: 10.1001/jama.2013.6285. View

Burke 3rd G, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A . Recurrence of autoimmunity following pancreas transplantation. Curr Diab Rep. 2011; 11(5):413-9. PMC: 4018301. DOI: 10.1007/s11892-011-0206-y. View

Masteller E, Warner M, Tang Q, Tarbell K, McDevitt H, Bluestone J . Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol. 2005; 175(5):3053-9. DOI: 10.4049/jimmunol.175.5.3053. View

10.

Hagopian W, Ferry Jr R, Sherry N, Carlin D, Bonvini E, Johnson S . Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013; 62(11):3901-8. PMC: 3806608. DOI: 10.2337/db13-0236. View

11.

Skyler J, Krischer J, Wolfsdorf J, Cowie C, Palmer J, Greenbaum C . Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005; 28(5):1068-76. DOI: 10.2337/diacare.28.5.1068. View

12.

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

13.

Malek T . The biology of interleukin-2. Annu Rev Immunol. 2007; 26:453-79. DOI: 10.1146/annurev.immunol.26.021607.090357. View

14.

Long S, Rieck M, Sanda S, Bollyky J, Samuels P, Goland R . Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes. 2012; 61(9):2340-8. PMC: 3425404. DOI: 10.2337/db12-0049. View

15.

Hartemann A, Bensimon G, Payan C, Jacqueminet S, Bourron O, Nicolas N . Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014; 1(4):295-305. DOI: 10.1016/S2213-8587(13)70113-X. View

16.

Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, Grabowska M, Techmanska I, Juscinska J . Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care. 2012; 35(9):1817-20. PMC: 3425004. DOI: 10.2337/dc12-0038. View

17.

Schneider A, Rieck M, Sanda S, Pihoker C, Greenbaum C, Buckner J . The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol. 2008; 181(10):7350-5. PMC: 2597079. DOI: 10.4049/jimmunol.181.10.7350. View

18.

Tang Q, Henriksen K, Bi M, Finger E, Szot G, Ye J . In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004; 199(11):1455-65. PMC: 2211775. DOI: 10.1084/jem.20040139. View

19.

Burchill M, Yang J, Vang K, Moon J, Chu H, Lio C . Linked T cell receptor and cytokine signaling govern the development of the regulatory T cell repertoire. Immunity. 2008; 28(1):112-21. PMC: 2430111. DOI: 10.1016/j.immuni.2007.11.022. View

20.

Pociot F, Akolkar B, Concannon P, Erlich H, Julier C, Morahan G . Genetics of type 1 diabetes: what's next?. Diabetes. 2010; 59(7):1561-71. PMC: 2889752. DOI: 10.2337/db10-0076. View